Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia (Metamemory 2)

July 25, 2017 updated by: University Hospital, Clermont-Ferrand

The purpose of this study is to determine the respective roles of aging and schizophrenia in the regulation of metamemory using a sentence construction strategy. 4 groups will be necessary to comparison:

Adult patients (18-45 years) Adult controls (18-45 years) Aged patients (≥ 55 years) Aged controls (≥ 55 years)

The effects of age and the disease could lead to interaction in regulating metamemory. The effect of age would be aggravated by the disease.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Metamemory measurement

  • Objective: Measurement of monitoring and control capabilities, and relations between these two abilities when learning of word pairs.
  • Description: The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.

In front of a computer screen, each participant is subjected to a first learning test in which 30 pairs of words appear one by one on the screen. Participants have the option to control the time of presentation of each pair of words. After a retention time of 4 minutes of information devoted to nonverbal distractive task, follows an evaluation phase of deferred judgments of learning (JOL time), where for each pair of words studied, the word index is presented without the target word. Participants must then assess a learning judgment for each pair of words, that is to say they have to estimate, on a 5-point scale, their ability to remember later the target word in the presentation the index word. This JOL (judgments of learning ) assessment phase is immediately followed by cued recall test.

For the second learning test (30 other word pair), the steps are identical. Prior to this second learning, building instruction of a phrase with two words to learn is proposed. Participants are trained on 5 pairs of words. The study concludes with a question phase, during which participants give their impressions of the experience, describe the learning strategies they used and generally consider their ability mnemonic during daily tasks.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Clermont-Ferrand, France, 63003
        • Recruiting
        • CHU Clermont-Ferrand

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • For both:
  • MMSE score greater than or equal to,

    • 22 if no grade
    • 23 if study certificate or CAP or college without patent
    • 25 if patent or school without the tray
    • 26 or more when bin
  • IQ ≥ 75 (fNART)
  • Age: between 18 and 45 years for adults, and 55 and older for older,

For patients :

  • DSM-5 criteria of schizophrenia
  • Adult patients (<45 years) will be matched to elderly patients (> 55 years) gender and IQ,
  • Patients followed as outpatients,
  • Age of onset of the disease less than 40 years,
  • Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month
  • Not more of a benzodiazepine,
  • Patients on protection of justice or not,

For controls :

  • - Matched for sex to patient
  • Age-matched (+/- 3 years) to patient
  • Matched for IQ (score fNART +/- 10%) to patients

Exclusion Criteria:

  • For patients :
  • Any other comorbid psychiatric diagnosis of Axis I DSM-5
  • Extrapyramidal syndrome or tardive dyskinesia (AIMS score <2 BARS score <2 and score Simpson and Angus <3)
  • Calgary depression scale ≥ 6
  • Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco.
  • Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis).
  • Use of alcohol or cannabis before the age of 15 years
  • Alcohol abuse in the past 6 months.
  • Cannabis abuse in the past 6 months and cannabis use in the last 3 months.
  • Patients with impaired vision or hearing preventing the realization of the tests.

For controls:

  • Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco)
  • Score HADS Anxiety ≥ 8 and Depression ≥ 8
  • SCL90R: global severity score GSI> 0.33 for women and> 0.27 for men, or score diversity PST symptoms> 18.49 for men and> 21.97 for women or score of degree of discomfort PSDI> 1.27 for men and> 1.3 for women, scoring in the subscale Psychotic Features> 0.
  • Presence of a personality disorder at PDQ4 +
  • Head injuries, brain injuries or diseases,
  • vision or hearing problems preventing the realization of the tests.
  • Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco.
  • Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis).
  • Long-term Anticholinergic treatment.
  • Related to the first degree diagnosed with a psychotic disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Adult schizophrenic patients (18-45 years)
4 groups formed by the case-control study in two age strata
Metamemory evaluation using a sentence construction strategy
EXPERIMENTAL: Aged patients with schizophrenia (≥ 55 years)
4 groups formed by the case-control study in two age strata
Metamemory evaluation using a sentence construction strategy
EXPERIMENTAL: Adults controls (18-45 years)
4 groups formed by the case-control study in two age strata
Metamemory evaluation using a sentence construction strategy
EXPERIMENTAL: Aged Controls (≥ 55 years)
4 groups formed by the case-control study in two age strata
Metamemory evaluation using a sentence construction strategy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy
Time Frame: at day 1

the 4 groups of participants formed by the case-control study in two age strata value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy.

Four groups are :

  • Adult schizophrenic patients (18-45 years)
  • Aged patients with schizophrenia (≥ 55 years)
  • Adults controls (18-45 years)
  • Aged controls (≥ 55 years)
at day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) between sentence construction and reading strategies.
Time Frame: at day 1

the 4 groups of participants formed by the case-control study in two age strata, value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in a sentence construction strategy and in a reading strategy.

For each group, difference between these two strategies will be compared.

Four groups are :

  • Adult schizophrenic patients (18-45 years)
  • Aged patients with schizophrenia (≥ 55 years)
  • Adults controls (18-45 years)
  • Aged controls (≥ 55 years)
at day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Isabelle JALENQUES, CHU Clermont-Ferrrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 19, 2017

Primary Completion (ANTICIPATED)

February 1, 2020

Study Completion (ANTICIPATED)

September 1, 2020

Study Registration Dates

First Submitted

October 4, 2016

First Submitted That Met QC Criteria

October 12, 2016

First Posted (ESTIMATE)

October 13, 2016

Study Record Updates

Last Update Posted (ACTUAL)

July 27, 2017

Last Update Submitted That Met QC Criteria

July 25, 2017

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • CHU-0280
  • 2016-A00944-47 (OTHER: 2016-A00944-47)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Metamemory

3
Subscribe